Engage with the Elata Biosciences process

Elata is dedicated to working with the best neuropsychiatric drug developers through academic, private, and public efforts. If you're a drug developer in neuropsychiatry, reach out to us.
Submit interest
Active programs

Core tenants of Elata-initiated development efforts

Diversified, de-risked, and innovative

It's no secret that drug development is risky and oftentimes, prone to failure. Our strategy provides immense downside protection to our tokenholders and ensures operational continuity through pursuing projects where some form of mechanistically-validating data is present. By finding the balance between novelty and proof, we aim to be at the forefront of all efforts across neuropsychiatry.

We are particularly interested in Fixed-Drug Combinations (FDCs) of already marketed medicines, channelopathies (ion-channel targeting) and GPCR-targeting small molecules.

Focus on precision and personalization

Neuropsychiatry has long struggled to gather well-targeted and homogenous patient populations, leaving a high level of variance in results throughout the entire pipeline.

With a new wealth of basic and clinical science rapidly emerging in the field of psychiatry, we believe that the time for precision medicine in neuropsychiatry is now.

In taking this approach, we believe that perfect alignment amongst constituents is imminent: patients receive more tailored (and efficacious) medicines, leading to higher prescription volume, market share, sales, and therefore, return on investment.

High unmet medical need

In many areas throughout neuropsychiatry, there are conditions where only a few corresponding drug development efforts are underway globally. Elata aims to fill the gaps in the market by supporting and capitalizing those aligned in our efforts to develop medicines in areas where there is deep and wavering unmet medical need for new solutions.

Programs

Coming Soon
See roadmap for expected date of announcement.
Development & Due Diligence Process

Learn more about how Elata ensures scientific integrity, selects projects, and incorporates them into the mission

1. Signal

We acquire project signal through community RFPs, external project submissions, Elata contributors, or our Development team will find it.

2. Initial Screening

The Elata Development team will review the project to ensure that it aligns with our overarching mission: potential for high downstream ROI, neuropsychiaty indication with high unmet need, and sufficient basic research or clinical data backing the mechanism of action.

3. Independent Review

If the project passes step 2, then the Elata Development team will present it to an independent review board of expert scientists and clinicians that will give it a second review to ensure scientific integrity and likelihood of success.

4. Community Presentation

Elata will present the project to its community as a way of gauging interest.

5. Tokenholder Vote

Elata Tokenholders will cast a binary (yes or no) vote to move the project forward. This will be performed on-chain through a platform known as Snapshot.

Technical & Science FAQs

Learn more about how we operate due diligence and initiate development programs. If you have any questions that aren't answered here, contact us.
Who does Elata work with?
Elata works exclusively on therapeutics development efforts in neuropsychiatry. This includes antipsychotics, antidepressants, anxiolytics, and other therapeutics in neuropsychiatry. Due to the complexity surrounding therapeutics in this area, Elata remains mainly focused on small-molecule modalities. We will consider alternative modalities, such as larger protein and antibody therapeutics, if there is reason to believe that clinical success can be achieved.

As our mission is to ensure sustainability for the initiative, we hope to build out a diversified development pipeline over time. Therefore, we will consider a wider variety of projects and equity exchanges, such as those that are for 505(b)(2) drug candidates, royalty acquisitions, and later-stage development projects, if they align with our overarching mission.

If there is a medicinal chemistry component and potential for therapeutics development downstream, we may also consider TechBio efforts for psychiatry-relevant biomarkers or drug delivery.
How do I get my project funded?
If you are a Principal Investigator (PI) or are working with a PI at a relevant lab, we request that you submit the following information to us:

- Why your project is able to achieve commercial success
- The unmet need it solves (problem and solution)
- How your project is innovative and provides a sizeable advantage over the incumbent
- The total budget your project requires followed by milestones, how much each milestone costs, and all information pertaining to intellectual property generation and retention
‍
To get further details on the process and how we can work together, you can contact Elata stewards here. Upon contact, you will be given further information on how you can work with Elata to ensure that goals are being met on both sides.
Why a DAO instead of a C-Corp or NGO?
A DAO is the most sensible solution to our issue, as it effectively combines aspects of centralization and decentralization, is modular, and generally adopts characteristics from corporations and non-profits while remaining fundamentally distinct from both.

With regards to neuropsychiatry, the field has long struggled with data silos, poor alignment of incentives, riskiness, and innovation. Corporations have divested from neuropsychiatry and struggle with incentive alignments whereas non-profits and public spinouts struggle heavily with efficiency, human capital, and productization.

We believe Elata is a practical way to solve issues in neuropsychiatry for the following reasons:

• A DAO is decentralized, open-source, and perhaps even more focused on ethics, meaning anyone (especially patients) can contribute to and partake in upside of successful drug development efforts on-chain.

• Is able to cover the intense costs typically associated with drug development using funds from the DAO treasury.

• Is scalable, modular (many initiatives can be executed simultaneously), and in turn, more efficient.